Junshi Bio (01877) announced on August 30, 2024 that as part of the restructuring of Shanghai Anlingke, the company plans to enter into a restructuring framework agreement with Shanghai Anlingke, Feng Hui, Shanghai Lingkeyixin, Shanghai Anling Xiuxu, Med-Fine Venture Fund I, L.P., Allied Pulse Investment Holding Limited, Changzhou Jifeng, and Wuhan Jifeng, according to which the company (or its controlling entity) will sell approximately 9.45% of the equity of Shanghai Anlingke to Anlingke Hong Kong for a price of RMB 30.5978 million. Additionally, the company (or its controlling entity) will subscribe, and Anlingke Cayman will issue a subscription warrant, giving the right to subscribe for a total of 14 million shares of Anlingke Cayman's subscription warrant shares, accounting for approximately 9.45% of the issued share capital of Anlingke Cayman.
Junshi Bio (01877) announced on August 30, 2024 that as part of the restructuring of Shanghai Anlingke, the company plans to enter into a restructuring framework agreement with Shanghai Anlingke, Feng Hui, Shanghai Lingkeyixin, Shanghai Anling Xiuxu, Med-Fine Venture Fund I, L.P., Allied Pulse Investment Holding Limited, Changzhou Jifeng, and Wuhan Jifeng, according to which the company (or its controlling entity) will sell approximately 9.45% of the equity of Shanghai Anlingke to Anlingke Hong Kong for a price of RMB 30.5978 million. Additionally, the company (or its controlling entity) will subscribe, and Anlingke Cayman will issue a subscription warrant, giving the right to subscribe for a total of 14 million shares of Anlingke Cayman's subscription warrant shares, accounting for approximately 9.45% of the issued share capital of Anlingke Cayman.
After the completion of the transaction, the company will no longer hold any equity in Shanghai Anlingke, but will hold approximately 9.45% of the issued share capital of Anlingke Cayman.
The announcement stated that the proposed transaction under the restructuring framework agreement is intended to promote overseas financing and business development. Through the restructuring, Anlingke Cayman aims to expand its channels for obtaining more diverse sources of funding, enhance its ability to enter the international market, and strengthen its long-term global competitiveness, which is in the interest of the company as one of its shareholders.
Shanghai Anlingke is a limited company established in China in 2023, primarily engaged in the development of bispecific antibodies and antibody-drug conjugates.
Anlingke Cayman is a limited company registered and established in the Cayman Islands, primarily engaged in the research and development of bispecific antibodies and antibody-drug conjugates.